Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Wojciech Jurczak(Jagiellonian University), Manish R. Patel(Sarah Cannon), Jonathon B. Cohen(Emory University), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Deepa Jagadeesh(University of Massachusetts Chan Medical School), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Minal Barve(Mary Crowley Cancer Research Center), Jennifer R. Brown(Dana-Farber Cancer Institute), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Suchitra Sundaram(Roswell Park Comprehensive Cancer Center), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Omar Abdel‐Wahab(Memorial Sloan Kettering Cancer Center), Donald E. Tsai(University of Pennsylvania), Binoj C. Nair(Eli Lilly (United States)), Constantine S. Tam(The Alfred Hospital), James N. Gerson(UPMC Hillman Cancer Center), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Toby A. Eyre(Oxford University Hospitals NHS Trust), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Matthew S. Davids(Dana-Farber Cancer Institute), Chan Y. Cheah(The University of Western Australia), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), Stephen J. Schuster(Hospital of the University of Pennsylvania), Bita Fakhri(University of California, San Francisco), Alvaro J. Alencar(University of Miami), Paolo Ghia(Vita-Salute San Raffaele University), Nirav N. Shah(Medical College of Wisconsin), Justin Taylor(Medical University of South Carolina), William G. Wierda(University of Maryland, Baltimore), David Lewis(University Hospitals Plymouth NHS Trust), John M. Pagel, Edward Y. Zhu(Memorial Sloan Kettering Cancer Center), Ian W. Flinn(Tennessee Oncology), Tahla Munir(St James's University Hospital), Denise Wang(Eli Lilly (United States))
Cited by 15
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k